･ subarachnoid hemorrhage Eleven patients (6 women; mean age of 63.8 ± 6.4 years [range, 50-73 years]) were enrolled in the study. Endovascular cooling was initiated at 7.9 ± 1.4 days (range, 6-11 days) after admission and continued for 6.7 ± 0.9 days (range 4-7 days). Unfavorable outcomes were associated with minimal shivering and good temperature control, whereas favorable outcomes were associated with vigorous shivering and increased temperature. Nine patients manifested shivering with increased temperature and were treated with acetaminophen, dexmedetomidine, and/or propofol. During the study period,
two patients developed fevers above 38°C, and 8 of 11 patients without endovascular cooling developed fevers (p=0.03, two-tailed Fisher's exact test). There was no evidence of cerebral infarction related to vasospasm during endovascular cooling, and no catheter-related sepsis or thromboembolic events. In one patient, fasudil hydrochloride was administered intra-arterially for angiographic vasospasm, resulting in no cerebral infarction. In another patient, intensive treatment was withdrawn because of massive brain swelling; however, slight but extensive early ischemic change was retrospectively confirmed on computed tomography prior to endovascular cooling. Vasospasm-related cerebral infarction occurred in one patient 2 days after removal of the cooling catheter. In one patient, fatal bacterial meningitis related to spinal drainage occurred on Day 29. Three-month outcomes showed good recovery in 2, moderate disability in 4, severe disability in 2, vegetative state in 1, and death in 2.
Amelioration of fever burden during the first 14 days after onset of SAH was safe and feasible with combined surface and endovascular cooling in patients with WFNS Grade 5 SAH. This patient became alert during endovascular temperature management, making possible bedside neurological assessment to evaluate potential deterioration due to delayed cerebral ischemia. 
